{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:37:02Z","timestamp":1784000222822,"version":"3.55.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"49","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Environ Sci Pollut Res"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11356-022-22830-2","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T03:29:16Z","timestamp":1663126156000},"page":"73809-73827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Focusing the pivotal role of nanotechnology in Huntington\u2019s disease: an insight into the recent advancements"],"prefix":"10.1007","volume":"29","author":[{"given":"Sukhbir","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishrat","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj Kumar","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendran","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkanya","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vetriselvan","family":"Subramaniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal M","family":"Alsubayiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed Ghaleb","family":"Dailah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer","family":"Naved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Harrasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Aleya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"22830_CR1","unstructured":"Arasappan A, Cox JM, Debenham JS, Guo Z, Lai Z, Meng D (2022) Cyclobutyl pyrazolopyrimidine PDE9 inhibitors. US20220017525"},{"key":"22830_CR2","doi-asserted-by":"crossref","unstructured":"Ba\u00f1ez-Coronel M, Ayhan F, Tarabochia AD, Zu T, Perez BA, Tusi SK., Ranum LPW (2015). RAN translation in Huntington disease. Neuron 88: 667\u2013677. http:\/\/doi.org\/10.1016\/j.neuron.2015.10.038","DOI":"10.1016\/j.neuron.2015.10.038"},{"key":"22830_CR3","doi-asserted-by":"crossref","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Tabrizi SJ (2015) Huntington disease. Nat Rev Dis Primers 15005. http:\/\/doi.org\/10.1038\/nrdp.2015.5","DOI":"10.1038\/nrdp.2015.5"},{"key":"22830_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pharmthera.2004.08.001","volume":"104","author":"DJ Begley","year":"2004","unstructured":"Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29\u201345. https:\/\/doi.org\/10.1016\/j.pharmthera.2004.08.001","journal-title":"Pharmacol Ther"},{"key":"22830_CR5","unstructured":"Bennett CF, Norris DA, Smith AV, Lane R (2021) Methods for reducing Htt expression. WO2021168183"},{"key":"22830_CR6","doi-asserted-by":"publisher","first-page":"9142","DOI":"10.1158\/0008-5472.can-06-4690","volume":"67","author":"ME Bernardo","year":"2007","unstructured":"Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Locatelli F (2007) Human bone marrow\u2013derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67:9142\u20139149. https:\/\/doi.org\/10.1158\/0008-5472.can-06-4690","journal-title":"Cancer Res"},{"key":"22830_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3109\/10717544.2014.880860","volume":"22","author":"R Bhatt","year":"2015","unstructured":"Bhatt R, Singh D, Prakash A, Mishra N (2015) Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington\u2019s disease. Drug Deliv 22:931\u2013939. https:\/\/doi.org\/10.3109\/10717544.2014.880860","journal-title":"Drug Deliv"},{"key":"22830_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jconrel.2020.12.051","volume":"330","author":"G Birolini","year":"2021","unstructured":"Birolini G, Valenza M, Ottonelli I, Passoni A, Favagrossa M, Duskey JT, Bombaci M, Vandelli MA, Colombo L, Bagnati R, Caccia C (2021) Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington\u2019s disease. J Control Release 330:587\u2013598. https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.051","journal-title":"J Control Release"},{"key":"22830_CR9","unstructured":"Brownstein MJ (2020a) Compositions and methods for treating neurodegenerative diseases. SG10202001065S"},{"key":"22830_CR10","unstructured":"Brownstein MJ (2020b) Compositions and methods for treating neurodegenerative diseases. NZ724718"},{"key":"22830_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6:919\u2013930. https:\/\/doi.org\/10.1038\/nrn1806","journal-title":"Nat Rev Neurosci"},{"key":"22830_CR12","unstructured":"Chase TN, Clarence-Smith K (2020) Methods for developing pharmaceuticals for treating neurodegenerative conditions. US20200400687"},{"key":"22830_CR13","unstructured":"Chase TN, Clarence-Smith K (2021) Kinases as biomarkers for neurodegenerative conditions. WO2021138364"},{"key":"22830_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tips.2009.06.005","volume":"30","author":"F Cicchetti","year":"2009","unstructured":"Cicchetti F, Drouin-Ouellet J, Gross RE (2009) Environmental toxins and Parkinson\u2019s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 30:475\u2013483. https:\/\/doi.org\/10.1016\/j.tips.2009.06.005","journal-title":"Trends Pharmacol Sci"},{"key":"22830_CR15","doi-asserted-by":"publisher","first-page":"34725","DOI":"10.1021\/acsami.9b12319","volume":"11","author":"W Cong","year":"2019","unstructured":"Cong W, Bai R, Li YF, Wang L, Chen C (2019) Selenium nanoparticles as an efficient nanomedicine for the therapy of Huntington\u2019s disease. ACS Appl Mater Interfaces 11:34725\u201334735. https:\/\/doi.org\/10.1021\/acsami.9b12319","journal-title":"ACS Appl Mater Interfaces"},{"key":"22830_CR16","unstructured":"Cordeiro MF, Maddison J (2021) Method of diagnosis.WO2021148653"},{"key":"22830_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ncl.2014.09.003","volume":"33","author":"P Dayalu","year":"2015","unstructured":"Dayalu P, Albin RL (2015) Huntington disease. Neurol Clin 33:101\u2013114. https:\/\/doi.org\/10.1016\/j.ncl.2014.09.003","journal-title":"Neurol Clin"},{"key":"22830_CR18","doi-asserted-by":"publisher","first-page":"24126","DOI":"10.1021\/acsami.7b06510","volume":"9","author":"K Debnath","year":"2017","unstructured":"Debnath K, Pradhan N, Singh BK, Jana NR (2017) Poly(trehalose) Nanoparticles prevent amyloid aggregation and suppress polyglutamine aggregation in a Huntington\u2019s disease model mouse. ACS Appl Mater Interfaces 9:24126\u201324139. https:\/\/doi.org\/10.1021\/acsami.7b06510","journal-title":"ACS Appl Mater Interfaces"},{"key":"22830_CR19","unstructured":"Delmedico MK (2021) Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier. US20210212996"},{"key":"22830_CR20","doi-asserted-by":"publisher","first-page":"8287","DOI":"10.1371\/journal.pone.0008287","volume":"4","author":"C Deyts","year":"2009","unstructured":"Deyts C, Galan-Rodriguez B, Martin E, Bouveyron N, Roze E, Charvin D, B\u00e9tuing S (2009) Dopamine D2 Receptor Stimulation potentiates PolyQ-huntingtin-induced mouse striatal neuron dysfunctions via Rho\/ROCK-II activation. PLoS ONE 4:8287. https:\/\/doi.org\/10.1371\/journal.pone.0008287","journal-title":"PLoS ONE"},{"key":"22830_CR21","unstructured":"Dubowchik GM, Lundquist JT, Mcwherter MA, Pelletier JC, Reitz AB, Strobel E, Zhang Y (2021) Prodrugs of myeloperoxidase inhibitors. WO2021072140"},{"key":"22830_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","volume":"62","author":"K Duff","year":"2007","unstructured":"Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC (2007) Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the predict-HD study. Biol Psychiatry 62:1341\u20131346. https:\/\/doi.org\/10.1016\/j.biopsych.2006.11.034","journal-title":"Biol Psychiatry"},{"key":"22830_CR23","unstructured":"Duffield AJ, Pandya A (2021) Pharmaceutical compounds for use in treating Huntington\u2019s disease. US20210236479"},{"key":"22830_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7150\/thno.5477","volume":"3","author":"M Edmundson","year":"2013","unstructured":"Edmundson M, Thanh NT, Song B (2013) Nanoparticles based stem cell tracking in regenerative medicine. Theranostics 3:573\u2013582. https:\/\/doi.org\/10.7150\/thno.5477","journal-title":"Theranostics"},{"key":"22830_CR25","doi-asserted-by":"publisher","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","volume":"10","author":"MG Erkkinen","year":"2018","unstructured":"Erkkinen MG, Kim MO, Geschwind MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 10:a033118. https:\/\/doi.org\/10.1101\/cshperspect.a033118","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"22830_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR (2014) Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord. 29:105\u2013114. https:\/\/doi.org\/10.1002\/mds.25717","journal-title":"Mov Disord."},{"key":"22830_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","volume":"37","author":"R Gabathuler","year":"2010","unstructured":"Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 37:48\u201357. https:\/\/doi.org\/10.1016\/j.nbd.2009.07.028","journal-title":"Neurobiol Dis."},{"key":"22830_CR28","unstructured":"Gamolski A (2021) Gene-therapy Dna Vector. WO2021145793"},{"key":"22830_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3329\/icpj.v1i11.12065","volume":"1","author":"A Garud","year":"2012","unstructured":"Garud A, Singh D, Garud N (2012) Solid lipid nanoparticles (SLN): method, characterization and applications. Int Curr Pharm J 1:384\u2013393. https:\/\/doi.org\/10.3329\/icpj.v1i11.12065","journal-title":"Int Curr Pharm J"},{"key":"22830_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/jhd-159001","volume":"4","author":"KE Glajch","year":"2015","unstructured":"Glajch KE, Sadri-Vakili G (2015) Epigenetic mechanisms involved in Huntington\u2019s disease pathogenesis. J Huntington\u2019s dis 4:1\u20135. https:\/\/doi.org\/10.3233\/jhd-159001","journal-title":"J Huntington\u2019s dis"},{"key":"22830_CR31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1021\/mp3003946","volume":"10","author":"BM Godinho","year":"2013","unstructured":"Godinho BM, Ogier JR, Darcy R, O\u2019Driscoll CM, Cryan JF (2013) Self-assembling modified \u03b2-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington\u2019s disease. Mol Pharm 10:640\u2013469. https:\/\/doi.org\/10.1021\/mp3003946","journal-title":"Mol Pharm"},{"key":"22830_CR32","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.molcel.2004.09.016","volume":"15","author":"H Goehler","year":"2004","unstructured":"Goehler H, Lalowski M, Stelzl U, Waelter S, Stroedicke M, Worm U, Wanker EE (2004) A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington\u2019s disease. Mol Cell 15:853\u2013865. https:\/\/doi.org\/10.1016\/j.molcel.2004.09.016","journal-title":"Mol Cell"},{"key":"22830_CR33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.33263\/BRIAC121.618637","volume":"112","author":"IK Grewal","year":"2021","unstructured":"Grewal IK, Singh S, Arora S, Sharma N (2021) Application of central composite design for development and optimization of eflornithine hydrochloride-loaded sustained release solid lipid microparticles. Biointerface Res Appl Chem. 112:618\u2013637. https:\/\/doi.org\/10.33263\/BRIAC121.618637","journal-title":"Biointerface Res Appl Chem."},{"key":"22830_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/mds.26001","volume":"29","author":"JF Gusella","year":"2014","unstructured":"Gusella JF, MacDonald ME, Lee JM (2014) Genetic modifiers of Huntington\u2019s disease. Mov Disord 29:1359\u20131365. https:\/\/doi.org\/10.1002\/mds.26001","journal-title":"Mov Disord"},{"key":"22830_CR35","unstructured":"Hall A, Maccoss M (2018) Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation. MYPI2019003807"},{"key":"22830_CR36","unstructured":"Hall A, Maccoss M, Provins L (2018) Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation. MYPI2019003756"},{"key":"22830_CR37","doi-asserted-by":"publisher","unstructured":"Hanumanaik M, Patel S, Ramya SK (2013) Solid lipid nanoparticles a review. IJPSR 4: 928-940. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.4(3).928-40","DOI":"10.13040\/IJPSR.0975-8232.4(3).928-40"},{"key":"22830_CR38","unstructured":"Harriott N, Pagano N (2018) N [2 (1 benzylpiperidin 4 Yl) ethyl] 4(Pyrazin 2 Yl) piperazine 1 carboxamide derivatives and related compounds as muscarinic receptor 4 (M4) antagonists for treating neurological diseases. IN201817017739"},{"key":"22830_CR39","unstructured":"Hilmar B, Jing Y (2021) Novel means to modulate NMDA receptor-mediated toxicity. EP3867267"},{"key":"22830_CR40","unstructured":"Hwang S, Jani M, Babu S, Sydorenko N, Moon Y, Bhattacharyya A (2019) Methods for treating Huntington\u2019s disease. PH1\/2018\/501226"},{"key":"22830_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13803390600718958","volume":"29","author":"KF Hoth","year":"2007","unstructured":"Hoth KF, Paulsen JS, Moser DJ, Tranel D, Clark LA, Bechara A (2007) Patients with Huntington\u2019s disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuro psychol 29:365\u2013376. https:\/\/doi.org\/10.1080\/13803390600718958https:\/\/clinicaltrials.gov","journal-title":"J Clin Exp Neuro psychol"},{"key":"22830_CR42","unstructured":"Howard C, Emmanuel OA, Nchekwube Emeka N, Olusola O (2018) Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases. EP3267992"},{"key":"22830_CR43","unstructured":"John V, Bilousova T, Simmons B, Garg N, Campagna J, Jagodzinska B (2021) Compositions and methods for the treatment of neurodegenerative diseases. WO2021142221"},{"key":"22830_CR44","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.drudis.2008.09.005","volume":"13","author":"L Juillerat-Jeanneret","year":"2008","unstructured":"Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs across the blood\u2013brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov 13:1099\u20131106. https:\/\/doi.org\/10.1016\/j.drudis.2008.09.005","journal-title":"Drug Discov"},{"key":"22830_CR45","unstructured":"Kaku H, Rothstein TL (2021) Treatment of neurodegenerative proteinopathies using Fas apoptosis inhibitory molecule (Faim) Or a fragment and\/or a mimetic thereof. WO2021151011"},{"key":"22830_CR46","unstructured":"Karoly N, Sakura MS, Steven PB (2018) Methods and compositions for treating aging-associated impairments using Ccr3-inhibitors.MYPI2019005870"},{"key":"22830_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/156652408784221298","volume":"8","author":"M Katsuno","year":"2008","unstructured":"Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Tanaka F, Sobue G (2008) Molecular genetics and biomarkers of polyglutamine diseases. Curr Mol Med 8:221\u2013234. https:\/\/doi.org\/10.2174\/156652408784221298","journal-title":"Curr Mol Med"},{"key":"22830_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jconrel.2006.12.012","volume":"118","author":"J Kreuter","year":"2007","unstructured":"Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K (2007) Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release 118:54\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2006.12.012","journal-title":"J Control Release"},{"key":"22830_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/nano7090243","volume":"7","author":"J Kudr","year":"2017","unstructured":"Kudr J, Haddad Y, Richtera L, Heger Z, Cernak M, Adam V, Zitka O (2017) Magnetic nanoparticles: from design and synthesis to real world applications. Nanomaterials 7:243. https:\/\/doi.org\/10.3390\/nano7090243","journal-title":"Nanomaterials"},{"key":"22830_CR50","unstructured":"Laufer R, Summa V, Heller CJ (2022) Combination of cannabinoids with additional therapeutic agents for treating diseases or disorders. WO2022159507"},{"key":"22830_CR51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"JM Lee","year":"2015","unstructured":"Lee JM, Wheeler VC, Chao MJ, Vonsattel JPG, Pinto RM, Lucente D, Myers RH (2015) Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell 162:516\u2013526. https:\/\/doi.org\/10.1016\/j.cell.2015.07.003","journal-title":"Cell"},{"key":"22830_CR52","doi-asserted-by":"publisher","unstructured":"Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L (2017) Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev:1\u201311. https:\/\/doi.org\/10.1155\/2017\/2525967","DOI":"10.1155\/2017\/2525967"},{"key":"22830_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ (2018) Huntington\u2019s disease: a clinical review. Eur J Neurol 25:24\u201334. https:\/\/doi.org\/10.1111\/ene.13413","journal-title":"Eur J Neurol"},{"key":"22830_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","volume":"64","author":"W Mehnert","year":"2012","unstructured":"Mehnert W, M\u00e4der K (2012) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 64:83\u2013101. https:\/\/doi.org\/10.1016\/j.addr.2012.09.021","journal-title":"Adv Drug Deliv Rev"},{"key":"22830_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.scr.2012.05.005","volume":"9","author":"L Moraes","year":"2012","unstructured":"Moraes L, Vasconcelos-dos-Santos A, Santana FC, Godoy MA, Rosado-de-Castro PH, Jasmin, Mendez-Otero R (2012) Neuroprotective effects and magnetic resonance imaging of mesenchymal stem cells labeled with SPION in a rat model of Huntington\u2019s disease. Stem Cell Res 9:143\u2013155. https:\/\/doi.org\/10.1016\/j.scr.2012.05.005","journal-title":"Stem Cell Res"},{"key":"22830_CR56","doi-asserted-by":"publisher","first-page":"2003054","DOI":"10.1002\/adfm.202003054","volume":"30","author":"S Mukherjee","year":"2020","unstructured":"Mukherjee S, Madamsetty VS, Bhattacharya D, Roy Chowdhury S, Paul MK, Mukherjee A (2020) Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv Funct Mater 30:2003054. https:\/\/doi.org\/10.1002\/adfm.202003054","journal-title":"Adv Funct Mater"},{"key":"22830_CR57","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","volume":"54","author":"RH M\u00fcller","year":"2002","unstructured":"M\u00fcller RH, Radtke M, Wissing SA (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:S131\u2013S155. https:\/\/doi.org\/10.1016\/S0169-409X(02)00118-7","journal-title":"Adv Drug Deliv Rev"},{"key":"22830_CR58","unstructured":"Myers RH, Hoss A, Kartha VK (2018) Methods and assays relating to Huntington\u2019s disease. US20180282813"},{"key":"22830_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mrdd.1022","volume":"7","author":"MA Nance","year":"2001","unstructured":"Nance MA, Myers RH (2001) Juvenile onset Huntington\u2019s disease? Clinical and research perspectives. Dev Disabil Res Rev 7:153\u2013157. https:\/\/doi.org\/10.1002\/mrdd.1022","journal-title":"Dev Disabil Res Rev"},{"key":"22830_CR60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/01.nmd.0000106004.67587.57","volume":"192","author":"C Nehl","year":"2004","unstructured":"Nehl C, Paulsen JS (2004) Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis 192:72\u201374. https:\/\/doi.org\/10.1097\/01.nmd.0000106004.67587.57","journal-title":"J Nerv Ment Dis"},{"key":"22830_CR61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrn2995","volume":"12","author":"EA Neuwelt","year":"2011","unstructured":"Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D, Drewes LR (2011) Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12:169\u2013182. https:\/\/doi.org\/10.1038\/nrn2995","journal-title":"Nat Rev Neurosci"},{"key":"22830_CR62","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/B978-0-12-381328-2.00013-4","volume":"98","author":"MJ Novak","year":"2011","unstructured":"Novak MJ, Tabrizi SJ (2011) Huntington\u2019s disease: clinical presentation and treatment. Int Rev Neurobiol 98:297\u2013323. https:\/\/doi.org\/10.1016\/B978-0-12-381328-2.00013-4","journal-title":"Int Rev Neurobiol"},{"key":"22830_CR63","unstructured":"Oakes B, Higgins S, Spinner H, Denny S, Staahl BT, Taylor K, Baney K, Colin I, Adil M, Urnes C (2021) Compositions and methods for the targeting of HTT. WO2021113769"},{"key":"22830_CR64","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1602\/neurorx.2.1.108","volume":"2","author":"JC Olivier","year":"2005","unstructured":"Olivier JC (2005) Drug transport to brain with targeted nanoparticles. NeuroRX. 2:108\u2013119. https:\/\/doi.org\/10.1602\/neurorx.2.1.108","journal-title":"NeuroRX."},{"key":"22830_CR65","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/mdc3.13148","volume":"8","author":"M Oosterloo","year":"2021","unstructured":"Oosterloo M, de Greef BT, Bijlsma EK, Durr A, Tabrizi SJ, Estevez-Fraga C, de Die-Smulders CE, Roos RA (2021) Disease onset in Huntington\u2019s disease: when is the conversion? Mov Disord Clin Pract. 8:352\u2013360. https:\/\/doi.org\/10.1002\/mdc3.13148","journal-title":"Mov Disord Clin Pract."},{"key":"22830_CR66","doi-asserted-by":"publisher","unstructured":"Pardridge WM (2002) Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov 7: 5-7. https:\/\/doi.org\/10.1016\/s1359-6446(01)02082-7.","DOI":"10.1016\/s1359-6446(01)02082-7"},{"key":"22830_CR67","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/157016312799304552","volume":"9","author":"R Parhi","year":"2012","unstructured":"Parhi R, Suresh P (2012) Preparation and characterization of solid lipid nanoparticles-a review. Curr Drug Discov Technol 9:2\u201316. https:\/\/doi.org\/10.2174\/157016312799304552","journal-title":"Curr Drug Discov Technol"},{"key":"22830_CR68","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/jnnp-2013-305114","volume":"84","author":"JS Paulsen","year":"2013","unstructured":"Paulsen JS, Smith MM, Long JD (2013) Cognitive decline in prodromal Huntington disease: implications for clinical trials. J Neurol Neurosurg Psychiatry 84:1233\u20131239. https:\/\/doi.org\/10.1136\/jnnp-2013-305114","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"22830_CR69","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11481-006-9025-3","volume":"1","author":"Y Persidsky","year":"2006","unstructured":"Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood\u2013brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223\u2013236. https:\/\/doi.org\/10.1007\/s11481-006-9025-3","journal-title":"J Neuroimmune Pharmacol"},{"key":"22830_CR70","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jconrel.2006.10.015","volume":"117","author":"B Petri","year":"2007","unstructured":"Petri B, Bootz A, Khalansky A, Hekmatara T, M\u00fcller R, Uhl R, Kreuter J, Gelperina S (2007) Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release 117:51\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2006.10.015","journal-title":"J Control Release"},{"key":"22830_CR71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.conb.2015.01.020","volume":"33","author":"JL Plotkin","year":"2015","unstructured":"Plotkin JL, Surmeier DJ (2015) Corticostriatal synaptic adaptations in Huntington\u2019s disease. Curr Opin Neurobiol 33:53\u201362. https:\/\/doi.org\/10.1016\/j.conb.2015.01.020","journal-title":"Curr Opin Neurobiol"},{"key":"22830_CR72","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord. 27:1083\u20131091. https:\/\/doi.org\/10.1002\/mds.25075","journal-title":"Mov Disord."},{"key":"22830_CR73","unstructured":"Qian PY, Cheng A, Liu C, Ye W, Zhu G (2022) Novel compounds as potential therapeutic agents targeting various neurodegenerative diseases. US20220112180"},{"key":"22830_CR74","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s11011-018-0252-0","volume":"33","author":"S Ramachandran","year":"2018","unstructured":"Ramachandran S, Thangarajan S (2018) Thymoquinone loaded solid lipid nanoparticles counteracts 3-nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington\u2019s disease. Metab Brain Dis 33:1459\u20131470. https:\/\/doi.org\/10.1007\/s11011-018-0252-0","journal-title":"Metab Brain Dis"},{"key":"22830_CR75","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.2147\/ijn.s149022","volume":"13","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Archunan G, Sivakumar M, Tamil Selvan S, Fred AL, Kumar S, Padmanabhan P (2018) Theranostic applications of nanoparticles in neurodegenerative disorders. Int J Nanomedicine 13:5561\u20135576. https:\/\/doi.org\/10.2147\/ijn.s149022","journal-title":"Int J Nanomedicine"},{"key":"22830_CR76","unstructured":"Reidling J, Fury B, Thompson LM, Bauer G, Coleal-Bergum D (2021) Neural stem cell compositions and methods to treat neurodegenerative disorders. US20210228644"},{"issue":"6","key":"22830_CR77","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00115-015-4306-9","volume":"86","author":"JD Rollnik","year":"2015","unstructured":"Rollnik JD (2015 Jun 1) Huntington\u2019s disease. Der Nervenarzt. 86(6):725\u2013735. https:\/\/doi.org\/10.1007\/s00115-015-4306-9","journal-title":"Der Nervenarzt."},{"key":"22830_CR78","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/mds.24024","volume":"27","author":"A Rosenblatt","year":"2011","unstructured":"Rosenblatt A, Kumar BV, Mo A, Welsh CS, Margolis RL, Ross CA (2011) Age, CAG repeat length, and clinical progression in Huntington\u2019s disease. Mov Disord 27:272\u2013276. https:\/\/doi.org\/10.1002\/mds.24024","journal-title":"Mov Disord"},{"key":"22830_CR79","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Tabrizi SJ (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10:204\u2013216. https:\/\/doi.org\/10.1038\/nrneurol.2014.24","journal-title":"Nat Rev Neurol"},{"key":"22830_CR80","unstructured":"Ruth PF, Andrea CM, Jose SBM, Alicia MA (2021) Acylhydrazones for the treatment of neurological diseases. EP3858342"},{"key":"22830_CR81","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12017-013-8261-y","volume":"16","author":"R Sandhir","year":"2014","unstructured":"Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma S (2014) Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington\u2019s disease. Neuromolecular Med. 16:106\u2013118. https:\/\/doi.org\/10.1007\/s12017-013-8261-y","journal-title":"Neuromolecular Med."},{"key":"22830_CR82","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/pharmaceutics13081183","volume":"13","author":"MK Satapathy","year":"2021","unstructured":"Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH (2021) Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics 13:1183. https:\/\/doi.org\/10.3390\/pharmaceutics13081183","journal-title":"Pharmaceutics"},{"key":"22830_CR83","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/ncpneuro0606","volume":"3","author":"SA Schneider","year":"2007","unstructured":"Schneider SA, Walker RH, Bhatia KP (2007) The Huntington\u2019s disease-like syndromes: what to consider in patients with a negative Huntington\u2019s disease gene test. Nat Clin Pract Neurol 3:517\u2013525. https:\/\/doi.org\/10.1038\/ncpneuro0606","journal-title":"Nat Clin Pract Neurol"},{"key":"22830_CR84","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1399-0004.2006.00668.x","volume":"70","author":"A Semaka","year":"2006","unstructured":"Semaka A, Creighton S, Warby S, Hayden M (2006) Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet 70:283\u2013294. https:\/\/doi.org\/10.1111\/j.1399-0004.2006.00668.x","journal-title":"Clin Genet"},{"key":"22830_CR85","doi-asserted-by":"publisher","unstructured":"Sevick MA, Nativio DG, Mcconnell T (2005) Genetic testing of children for late onset disease. Camb Q HealthcEthics 14(01). https:\/\/doi.org\/10.1017\/s0963180105050061","DOI":"10.1017\/s0963180105050061"},{"key":"22830_CR86","doi-asserted-by":"publisher","first-page":"60459","DOI":"10.1007\/s11356-021-16570-y","volume":"28","author":"N Sharma","year":"2021","unstructured":"Sharma N, Zahoor I, Sachdeva M, Subramaniyan V, Fuloria S, Fuloria NK, Naved T, Bhatia S, Al-Harrasi A, Aleya L, Bungau S (2021) Deciphering the role of nanoparticles for management of bacterial meningitis: an update on recent studies. Environ Sci Pollut Res. 28:60459\u201360476. https:\/\/doi.org\/10.1007\/s11356-021-16570-y","journal-title":"Environ Sci Pollut Res."},{"key":"22830_CR87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/13696998.2022.2033493","volume":"25","author":"E Shaw","year":"2022","unstructured":"Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu JW, Budd N, Maturi B, Cowling T, Mestre TA (2022) Epidemiology and economic burden of Huntington\u2019s disease: a Canadian provincial public health system perspective. J Med Econ. 25:212\u2013219. https:\/\/doi.org\/10.1080\/13696998.2022.2033493","journal-title":"J Med Econ."},{"key":"22830_CR88","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.addr.2009.03.007","volume":"61","author":"VI Shubayev","year":"2009","unstructured":"Shubayev VI, Pisanic TR II, Jin S (2009) Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 61:467\u2013477. https:\/\/doi.org\/10.1016\/j.addr.2009.03.007","journal-title":"Adv Drug Deliv Rev"},{"key":"22830_CR89","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","volume":"86","author":"R Singh","year":"2009","unstructured":"Singh R, Lillard JW (2009) Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:215\u2013223. https:\/\/doi.org\/10.1016\/j.yexmp.2008.12.004","journal-title":"Exp Mol Pathol"},{"key":"22830_CR90","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/nbt1340","volume":"25","author":"H Soo Choi","year":"2007","unstructured":"Soo Choi H, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Frangioni JV (2007) Renal clearance of quantum dots. Nat Biotechnol 25:1165\u20131170. https:\/\/doi.org\/10.1038\/nbt1340","journal-title":"Nat Biotechnol"},{"key":"22830_CR91","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.mad.2005.09.012","volume":"127","author":"F Squitieri","year":"2006","unstructured":"Squitieri F, Frati L, CiarmielloA LS, Quarrell O (2006) Juvenile Huntington\u2019s disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mech Ageing Dev 127:208\u2013212. https:\/\/doi.org\/10.1016\/j.mad.2005.09.012","journal-title":"Mech Ageing Dev"},{"key":"22830_CR92","unstructured":"Stanek LM, Richards B, Palermo A, O'riordan CR (2019) Variant RNAi. MYPI2020001372"},{"key":"22830_CR93","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","volume":"19","author":"KL Sugars","year":"2003","unstructured":"Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet. 19:233\u2013238. https:\/\/doi.org\/10.1016\/S0168-9525(03)00074-X","journal-title":"Trends Genet."},{"key":"22830_CR94","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEjMoal1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A (2019) Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med 380:2307\u20132316. https:\/\/doi.org\/10.1056\/NEjMoal1900907","journal-title":"N Engl J Med"},{"key":"22830_CR95","doi-asserted-by":"publisher","unstructured":"Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Stout JC (2011) Biological and clinical changes in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10: 31\u201342. https:\/\/doi.org\/10.1016\/s1474-4422(10)70276-3.","DOI":"10.1016\/s1474-4422(10)70276-3"},{"key":"22830_CR96","unstructured":"Tanner LL, Hirayama LC, Nemirow JL, Nie AY, Sahasrabudhe KP, Turner CD (2021) Treatment methods using a combination of pantethine and A Vanin agonist. WO2021150958"},{"key":"22830_CR97","unstructured":"Tran LHL (2022) Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders. VN1\/084679"},{"key":"22830_CR98","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.15252\/emmm.201505413","volume":"7","author":"M Valenza","year":"2015","unstructured":"Valenza M, Chen JY, Di Paolo E, Ruozi B, Belletti D, Ferrari BC, Cattaneo E (2015) Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington\u2019s disease mice. EMBO Mol Medi 7:1547\u20131564. https:\/\/doi.org\/10.15252\/emmm.201505413","journal-title":"EMBO Mol Medi"},{"key":"22830_CR99","unstructured":"Valles-Sanchez A, Konstantinova PS (2020) A companion diagnostic to monitor the effects of gene therapy. WO2020104435"},{"key":"22830_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032568","volume":"7","author":"S Wagner","year":"2012","unstructured":"Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, Vogel T, Worek F, Pietrzik CU, Kreuter J, von Briesen H (2012) Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One 7:e32568. https:\/\/doi.org\/10.1371\/journal.pone.0032568","journal-title":"PLoS One"},{"key":"22830_CR101","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.03","volume":"1200","author":"B Wilson","year":"2008","unstructured":"Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B (2008) Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\u2019s disease. Brain Res 1200:159\u2013168. https:\/\/doi.org\/10.1016\/j.brainres.2008.01.03","journal-title":"Brain Res"},{"key":"22830_CR102","unstructured":"Wipf P, Ngo LK, Terrab L, Brodsky JL (2021) Heat shock protein modulators and anti-Huntington disease therapeutic agents. WO2021163513"},{"key":"22830_CR103","unstructured":"Wittkowski KM(2020) Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation. US20200268788"},{"key":"22830_CR104","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1093\/hmg\/ddaa184","volume":"29","author":"GE Wright","year":"2020","unstructured":"Wright GE, Caron NS, Ng B, Casal L, Casazza W, Xu X, Ooi J, Pouladi MA, Mostafavi S, Ross CJ, Hayden MR (2020) Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease. Hum Mol Genet 29:2788\u20132802. https:\/\/doi.org\/10.1093\/hmg\/ddaa184","journal-title":"Hum Mol Genet"},{"key":"22830_CR105","doi-asserted-by":"publisher","unstructured":"Wyant KJ, Ridder AJ, Dayalu P (2017). Huntington\u2019s disease-update on treatments. Curr Neurol Neurosci Rep 17. https:\/\/doi.org\/10.1007\/s11910-017-0739-9","DOI":"10.1007\/s11910-017-0739-9"},{"key":"22830_CR106","unstructured":"Xing H (2021a) 5-Ht2a receptor antagonist and application thereof in treating central nervous system diseases. WO2021147818"},{"key":"22830_CR107","unstructured":"Xing H (2021b) 5ht2a receptor antagonist and medical application thereof. Wo2021147909"},{"key":"22830_CR108","unstructured":"Xu L, Zhao G (2021) Neuroactive steroids and pharmaceutical composition containing the same. WO2021142477"},{"key":"22830_CR109","doi-asserted-by":"publisher","first-page":"119248","DOI":"10.1016\/j.biomaterials.2019.119248","volume":"216","author":"L Zhang","year":"2019","unstructured":"Zhang L, Wei PF, Song YH, Dong L, Wu YD, Hao ZY, Wen LP (2019) MnFe2O4 nanoparticles accelerate the clearance of mutant huntingtin selectively through ubiquitin-proteasome system. Biomaterials 216:119248. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119248","journal-title":"Biomaterials"}],"container-title":["Environmental Science and Pollution Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-022-22830-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11356-022-22830-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-022-22830-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T16:08:12Z","timestamp":1665418092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11356-022-22830-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":109,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["22830"],"URL":"https:\/\/doi.org\/10.1007\/s11356-022-22830-2","relation":{},"ISSN":["0944-1344","1614-7499"],"issn-type":[{"value":"0944-1344","type":"print"},{"value":"1614-7499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"18 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors have approved the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}